Paper Details

  1. Home
  2. Paper Details

Lorlatinib - Induced pulmonary arterial hypertension.

Author: CatherinotEmilie, ChabrolAlexandre, ChaumaisMarie Camille, CoudercLouis Jean, DoubreHélèe, FrabouletSéverine, FriardSylvie, HamidAbdul Momen, MayengaMarie, MetivierAnne-Cécile, MontaniDavid, RivaudElisabeth, SalvatorHélène, TcherakianColas

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Two cases of pulmonary arterial hypertension induced by lorlatinib, a tyrosine kinase inhibitor for lung cancer, are reported. This is the first time that a tyrosine kinase inhibitor for lung cancer has been associated with pulmonary arterial hypertension.
Paper Details　
Original Abstract of the Article :
We report here the first cases, to our knowledge, of pulmonary arterial hypertension induced by lorlatinib. It s t...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.lungcan.2018.03.023

データ提供：米国国立医学図書館（NLM）

Lorlatinib and Pulmonary Arterial Hypertension: A New Side Effect to Consider

Lorlatinib, a targeted therapy used to treat lung cancer, has emerged as a valuable weapon in the fight against this devastating disease. However, like many medications, it can come with side effects. This report highlights a rare but potentially serious side effect of lorlatinib: pulmonary arterial hypertension (PAH), a condition that affects the blood vessels in the lungs.

Unveiling Hidden Dangers: The Importance of Vigilance

This report serves as a reminder that even seemingly safe and effective medications can have unexpected side effects. It underscores the importance of vigilant monitoring and early detection in managing patients receiving lorlatinib therapy.

A Call for Caution: Navigating the Terrain of Side Effects

This case report highlights the importance of awareness and ongoing research to better understand the potential side effects of new medications. Like a desert traveler carefully navigating unfamiliar terrain, healthcare providers must be vigilant in monitoring their patients for any signs of adverse events.

Dr.Camel's Conclusion

This report sheds light on a newly identified potential side effect of lorlatinib therapy: PAH. This finding highlights the importance of continued research to understand the safety profile of new medications and the need for vigilant monitoring of patients receiving these therapies. By remaining vigilant, we can ensure that patients receive the best possible care and minimize the risk of unexpected complications.

Date :
  1. Date Completed 2019-07-22
  2. Date Revised 2021-12-04
Further Info :

Pubmed ID

29748016

DOI: Digital Object Identifier

10.1016/j.lungcan.2018.03.023

Related Literature

Article Analysis
・Side Effects of lorlatinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.